Please assess the completion status of the following clinical trial:

Trial Title: S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or pathologically confirmed breast cancer meeting one of the following criteria:~  * Locally advanced disease (stage IIIB disease, stage IIB/IIIA, or stage IIIC disease)~ * Inflammatory disease meeting the following two clinicopathologic criteria:~    * Diffuse erythema AND edema (peau d'orange) of the breast involving the majority of the skin of the breast, i.e., more than 50%~   * A biopsy demonstrating cancer either within the dermal lymphatics OR in the breast parenchyma itself~* HER2/neu-negative tumor as demonstrated by 0 or 1+ (weak or no staining) by DAKO, IHC, or equivalent test OR no gene amplification by FISH\*~  * 2+ by DAKO or IHC allowed provided FISH\* negative~* NOTE: \*A negative FISH test ratio is \< 1.8 or FISH HER2 gene copy \< 4.0; if only a positive or negative result is available from the FISH test, a negative result is acceptable for study entry~* Hormone receptor status known~PATIENT CHARACTERISTICS:~* Menopausal status not specified~* Zubrod performance status 0-2~* Granulocyte count \> 1,500/mm\^3~* ANC ≥ 1,500/mm\^3~* Platelet count \> 100,000/mm\^3~* Hemoglobin 9.0 g/dL~* Serum creatinine ≤ 1.5 times upper limit of normal (ULN)~* Bilirubin ≤ 1.5 mg/dL~* ALT and AST ≤ 3 times ULN~* Alkaline phosphatase ≤ 2.5 ULN (unless bone metastasis is present in the absence of liver metastasis)~* Urine protein:creatinine ratio ≤ 0.5 OR urine protein \< 1,000 mg on 24-hour urine collection~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* Able to take oral medications (e.g., no uncontrolled nausea, vomiting, or diarrhea, lack of physical integrity of the upper gastrointestinal tract, or malabsorption syndrome)~* QTc \< 500 msec by EKG~* LVEF normal by MUGA or ECHO (for patients with hypertension or for patients \> 60 years of age)~* NYHA class II cardiac function by baseline ECHO/MUGA (for patients who have received central thoracic radiotherapy that included the heart in the radiotherapy port, or for patients who have a history of class II heart failure but are asymptomatic on treatment are eligible)~* No history of stroke (cerebrovascular accident), transient ischemic attack, or cardiac event within the past 12 months, including any of the following:~  * Myocardial infarction (including severe/unstable angina)~ * Coronary/peripheral artery bypass graft~ * Symptomatic congestive heart failure~ * Pulmonary embolism~* No poorly controlled hypertension, defined as recurrent or persistent (≥ 24 hours) elevated blood pressure (i.e., systolic blood pressure ≥ 140 mm Hg and/or diastolic blood pressure ≥ 90 mm Hg)~* No other malignancy within the past 5 years except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer~* Peripheral neuropathy \< grade 2~PRIOR CONCURRENT THERAPY:~* No prior tyrosine kinase inhibitors~* More than 5 years since prior chemotherapy, radiotherapy, or biologic therapy (e.g., trastuzumab or bevacizumab) for invasive breast cancer~* At least 7 days since prior hormonal therapy~* At least 7 days since prior and no concurrent strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole) or grapefruit juice~* No concurrent CYP3A4 inducers (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. John's wort)~* No other concurrent therapy for the treatment of breast cancer except for bisphosphonates~* No concurrent brachytherapy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on day 1 and bevacizumab IV over 30- to 90-minutes on day 1 of weeks 1-12. Patients then receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1 and pegfilgrastim SC on day 2 of weeks 14, 16, 18, 20, 22, and 24.
- Arm 2 (Type: ACTIVE_COMPARATOR): Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on day 1 of weeks 1-12, and then receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1 and pegfilgrastim SC on day 2 of weeks 14, 16, 18, 20, 22, and 24.
- Arm 3 (Type: ACTIVE_COMPARATOR): Patients receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1 and pegfilgrastim SC on day 2 of weeks 1, 3, 5, 7, 9, and 11, and then receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on day 1 of weeks 14-25.

Based on this trial design, predict the completion outcome and termination type (if applicable).